Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial

• Published in: Pharmacotherapy Vol. 35; no. 2; p. 140
• Main Authors: Hirsh-Rokach, Bruria, Spectre, Galia, Shai, Ela, Lotan, Amit, Ritter, Amit, Al-Aieshy, Fadiea, Malmström, Rickard E, Varon, David, Alcalai, Ronny
• Format: Journal Article
• Language: English
• Published: United States 01.02.2015
• Subjects: Adult; Citalopram - pharmacology; Cross-Over Studies; Cytochrome P-450 CYP2C19 - drug effects; Cytochrome P-450 CYP2C19 - metabolism; Cytochrome P-450 CYP2C19 Inhibitors - pharmacology; Double-Blind Method; Drug Interactions; Fluvoxamine - pharmacology; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors - pharmacokinetics; Platelet Aggregation Inhibitors - pharmacology; Prodrugs; Serotonin Uptake Inhibitors - pharmacology; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Ticlopidine - pharmacology; Young Adult; clopidogrel; cytochrome P450; antiplatelets; pharmacodynamics; selective serotonin reuptake inhibitors

To assess the effect of two selective serotonin reuptake inhibitors (SSRIs), fluvoxamine and citalopram, that markedly differ in their level of cytochrome P450 (CYP) 2C19 inhibition, on the laboratory response to clopidogrel, a prodrug requiring metabolism by the CYP system, and especially CYP2C19,...